Analysts Set Scholar Rock Holding Co. (NASDAQ:SRRK) Target Price at $25.17

Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) have been assigned a consensus rating of “Buy” from the six research firms that are covering the company, Marketbeat reports. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $25.17.

A number of analysts have recently weighed in on the company. Piper Sandler reaffirmed an “overweight” rating and set a $28.00 price objective on shares of Scholar Rock in a research report on Tuesday, March 26th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Scholar Rock in a research report on Tuesday, March 19th. Wedbush reaffirmed an “outperform” rating and set a $23.00 price objective on shares of Scholar Rock in a research report on Tuesday, January 23rd. Truist Financial reissued a “buy” rating and issued a $20.00 target price on shares of Scholar Rock in a report on Wednesday, April 3rd. Finally, Raymond James began coverage on Scholar Rock in a report on Thursday, March 28th. They issued a “strong-buy” rating and a $30.00 target price on the stock.

Insider Activity at Scholar Rock

In related news, insider Mo Qatanani sold 2,512 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.74, for a total value of $39,538.88. Following the completion of the sale, the insider now owns 147,019 shares in the company, valued at $2,314,079.06. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, insider Mo Qatanani sold 2,512 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.74, for a total value of $39,538.88. Following the completion of the sale, the insider now owns 147,019 shares in the company, valued at $2,314,079.06. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Jay T. Backstrom sold 11,614 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.74, for a total transaction of $182,804.36. Following the completion of the transaction, the chief executive officer now directly owns 352,671 shares of the company’s stock, valued at $5,551,041.54. The disclosure for this sale can be found here. Insiders sold a total of 22,359 shares of company stock worth $351,931 over the last 90 days. Company insiders own 26.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in SRRK. Barclays PLC increased its stake in shares of Scholar Rock by 62.3% during the 3rd quarter. Barclays PLC now owns 32,318 shares of the company’s stock worth $230,000 after purchasing an additional 12,409 shares in the last quarter. Polar Capital Holdings Plc purchased a new position in shares of Scholar Rock during the 3rd quarter worth approximately $10,664,000. Alps Advisors Inc. increased its stake in shares of Scholar Rock by 4.1% during the 3rd quarter. Alps Advisors Inc. now owns 41,535 shares of the company’s stock worth $295,000 after purchasing an additional 1,628 shares in the last quarter. FMR LLC increased its stake in shares of Scholar Rock by 3.8% during the 3rd quarter. FMR LLC now owns 8,005,654 shares of the company’s stock worth $56,840,000 after purchasing an additional 291,156 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of Scholar Rock during the 3rd quarter worth approximately $153,000. 91.08% of the stock is owned by hedge funds and other institutional investors.

Scholar Rock Stock Up 4.1 %

Shares of NASDAQ SRRK opened at $14.53 on Monday. The firm has a market cap of $1.13 billion, a price-to-earnings ratio of -7.30 and a beta of 0.90. The company has a quick ratio of 8.80, a current ratio of 8.80 and a debt-to-equity ratio of 0.22. Scholar Rock has a 52-week low of $5.56 and a 52-week high of $21.17. The business’s 50 day moving average is $15.33 and its two-hundred day moving average is $14.45.

Scholar Rock (NASDAQ:SRRK) last announced its earnings results on Tuesday, March 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.01). Research analysts predict that Scholar Rock will post -2.01 EPS for the current year.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.